Medication info
Vildazone 50mg (Vildagliptin Nitric Acid Salt)

Vildazone 50mg (Vildagliptin Nitric Acid Salt)

Prescription medicationTabletOral
Ingredient · strength
Vildagliptin Nitrate›60.4mg / 1 tablet
Manufacturer / importer
Kyungbo Pharmaceutical Co., Ltd.
Appearance
White to light yellow round tablet
Packaging
Bottle - 30 tablets/bottle, Bottle - 60 tablets/bottle
Approval status
Active

MFDS item code 202106501 · Approved 2021.09.10 · Insurance code 665003120

Summary

Main use
Improvement of blood glucose control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
- When used as monotherapy or in combination with metformin in patients who have not previously received drug treatment for diabetes, this drug is administered at 50mg once daily in the morning, or at 100mg daily as 50mg twice daily, in the morning and evening. - When adequate glycemic control cannot be achieved with monotherapy with metformin or a thiazolidinedione, the recommended dose of this drug when used in combination with metformin or a thiazolidinedione is 100mg daily, administered as 50mg twice daily, in the morning and evening. - When adequate glycemic control cannot be achieved with sulfonylurea monotherapy, the recommended dose of this drug when used in combination with a sulfonylurea is 50mg once daily in the morning. In this patient group, administering vildagliptin 100mg once daily was not more effective than administering 50mg once daily. - When adequate glycemic control cannot be achieved with combination therapy of a sulfonylurea and metformin, the recommended dose of this drug as add-on therapy (third-agent therapy) is 100mg daily, administered as 50mg twice daily, in the morning and evening. - When adequate glycemic control cannot be achieved with insulin therapy (insulin alone or in combination with metformin), the recommended dose of this drug as add-on therapy is 100mg daily, administered as 50mg twice daily, in the morning and evening. - This drug may be taken with or without food, and doses greater than 100mg daily are not recommended. - When this drug is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. - If a dose of this drug is missed, take it as soon as remembered and take the next dose at the usual time. If remembered close to the time of the next dose, skip the missed dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment This drug is not recommended for patients with hepatic impairment whose ALT or AST levels exceed 2.5 times the upper limit of normal before treatment. Patients with renal impairment - Patients with mild renal impairment (creatinine clearance ≥50mL/min): No dose adjustment is necessary. - Patients with moderate or severe renal impairment or end-stage renal disease (ESRD): A dose of 50mg once daily is recommended. (Refer to section 2) under ‘3. General precautions’ in the Precautions for Use.)

Ingredients

Manufacturer
Kyungbo Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in type 2 diabetes mellitus

  • Problems with blood sugar control in patients with type 2 diabetes
View approved original text

This drug is used to assist patients with type 2 diabetes in controlling their blood sugar levels alongside diet and exercise therapy. It can be taken alone or in combination with other diabetes medications, helping to effectively manage blood sugar levels and improve health.

How to take

Adult dose

- When used as monotherapy or in combination with metformin in patients who have not previously received drug treatment for diabetes, this drug is administered at 50mg once daily in the morning, or at 100mg daily as 50mg twice daily, in the morning and evening. - When adequate glycemic control cannot be achieved with monotherapy with metformin or a thiazolidinedione, the recommended dose of this drug when used in combination with metformin or a thiazolidinedione is 100mg daily, administered as 50mg twice daily, in the morning and evening. - When adequate glycemic control cannot be achieved with sulfonylurea monotherapy, the recommended dose of this drug when used in combination with a sulfonylurea is 50mg once daily in the morning. In this patient group, administering vildagliptin 100mg once daily was not more effective than administering 50mg once daily. - When adequate glycemic control cannot be achieved with combination therapy of a sulfonylurea and metformin, the recommended dose of this drug as add-on therapy (third-agent therapy) is 100mg daily, administered as 50mg twice daily, in the morning and evening. - When adequate glycemic control cannot be achieved with insulin therapy (insulin alone or in combination with metformin), the recommended dose of this drug as add-on therapy is 100mg daily, administered as 50mg twice daily, in the morning and evening. - This drug may be taken with or without food, and doses greater than 100mg daily are not recommended. - When this drug is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. - If a dose of this drug is missed, take it as soon as remembered and take the next dose at the usual time. If remembered close to the time of the next dose, skip the missed dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment This drug is not recommended for patients with hepatic impairment whose ALT or AST levels exceed 2.5 times the upper limit of normal before treatment. Patients with renal impairment - Patients with mild renal impairment (creatinine clearance ≥50mL/min): No dose adjustment is necessary. - Patients with moderate or severe renal impairment or end-stage renal disease (ESRD): A dose of 50mg once daily is recommended. (Refer to section 2) under ‘3. General precautions’ in the Precautions for Use.)

Precautions

This drug should not be used in certain patients. For example, patients allergic to this drug's active ingredient or other components, type 1 diabetes patients, or patients with diabetic ketoacidosis should not be administered this drug. Furthermore, patients with a genetic disorder that prevents the breakdown of lactose should also avoid taking this drug. While using this drug, liver dysfunction or hepatitis may occur rarely, so regular liver function tests should be performed before and during administration. If liver function levels significantly deviate from the normal range or jaundice symptoms appear, the medication should be discontinued immediately. This drug can cause hypoglycemia, especially when taken in combination with insulin secretagogues such as sulfonylureas. Therefore, when used in combination, hypoglycemic symptoms should be carefully monitored, and the dosage of the insulin secretagogue may need to be adjusted accordingly. Some patients with heart failure need to be cautious when using this drug, especially those with severe heart failure, for whom it is not recommended. If any abnormal symptoms like blisters or ulcers appear on the skin while taking this medication, you should inform your healthcare provider immediately, and also discontinue use and go to the hospital if acute pancreatitis symptoms are suspected. Due to the possibility of symptoms like dizziness, caution should be taken when driving or operating machinery. Pregnant or breastfeeding women should avoid using this drug, and it is also not recommended for children or teenagers under 18 years of age. In case of an overdose, since there are no specific antidotes, it is important to receive appropriate treatment based on symptoms. This drug should be kept out of the reach of children, and it is advisable to avoid transferring it to other containers.

Side effects

  • Hepatitis
  • liver dysfunction
  • angioedema
  • tremors
  • headache
  • dizziness
  • fatigue
  • nausea
  • hypoglycemia
  • nasopharyngitis
Show 73 more
  • asthenia
  • constipation
  • weight gain
  • peripheral edema
  • gastroesophageal reflux
  • diarrhea
  • abdominal distension
  • chills
  • decreased blood sugar
  • sweating
  • pancreatitis
  • urticaria
  • blisters
  • exfoliative skin lesions
  • severe arthralgia
  • cutaneous vasculitis
  • upper respiratory infection
  • acute myocardial infarction
  • nodular arrhythmia
  • acute cholecystitis
  • pneumothorax
  • cholelithiasis
  • femur fracture
  • peripheral artery obstructive disease
  • supraventricular tachycardia
  • congestive heart failure
  • gastric ulcer
  • gastric cancer
  • increased INR
  • appendicitis
  • pulmonary edema
  • vertigo
  • chest discomfort
  • dyspnea
  • cough
  • dyspepsia
  • drowsiness
  • pruritus
  • dry mouth
  • vomiting
  • insomnia
  • renal impairment
  • lip blisters
  • hunger
  • sensory loss
  • spinal canal stenosis
  • abdominal pain
  • gastroenteritis
  • gastritis
  • gastric ulcer
  • belching
  • fatty liver
  • cholecystitis
  • hyperkalemia
  • hypertriglyceridemia
  • heart failure
  • cardiac hypertrophy
  • angina
  • cardiac arrest
  • renal cyst
  • lung cancer
  • leg pain
  • increased C-reactive protein
  • bullous pemphigoid
  • myalgia
  • paresthesia
  • fever
  • edema
  • elevated lipase levels
  • increased creatine phosphokinase
  • elevated AST
  • increased C-reactive protein
  • elevated myoglobin levels

Not everyone experiences these, and they can vary from person to person.

Storage

This drug may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is recommended to maintain storage temperatures between 1 degree and 30 degrees Celsius at room temperature to preserve the efficacy of the drug.

Appearance and packaging

Appearance

White to light yellow round tablet

Package unit

Bottle - 30 tablets/bottle, Bottle - 60 tablets/bottle

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.